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1. Introduction  
Human respiratory syncytial virus (HRSV) (Collins et al., 2007), a Pneumovirus of the 
Paramyxoviridae family is an enveloped virus containing a negative-sense, single-stranded 
RNA genome of 15.2 kilobases that is transcribed into 10mRNAs encoding 11 proteins 
because two overlapping open reading frames of M2 mRNA encode the M2-1 and M2-2 
proteins. N is the nucleocapsid protein; L, the catalytic subunit of the RNA-dependent RNA 
polymerase, M2-1 transcription factor and the P phosphoprotein are components of the 
polymerase complex. M2-2 is a regulatory factor in RNA synthesis whereas M is the matrix 
protein. The non structural proteins NS1 and NS2 are antagonists of host type I interferons 
(IFN). Lastly F, G and SH are three transmembrane proteins. 
HRSV is the single most important cause of serious lower respiratory tract illnesses such as 
bronchiolitis and pneumonia in infants and young children (Hall, 2001; Shay et al., 2001; 
Thompson et al., 2003). In these acute lower respiratory infections due to HRSV, the case 
fatality ratio in children younger than 1 year of industrialised or developing countries is the 
0.7% and 2.1% respectively (Nair et al., 2010). Worldwide mortality from HRSV infection has 
been estimated in about 66,000 to 199,000 deaths annually in young children (Nair et al., 2010). 
In addition, infections of this virus occur in people of all ages, but although usually mild 
infections are reported in healthy adults, HRSV poses a serious health risk in 
immunocompromised individuals (Ison & Hayden, 2002; Wendt & Hertz, 1995) and in the 
elderly (Falsey et al., 2005; Han et al., 1999). In the United States, HRSV is estimated to cause 
approximately 13,000 annual deaths among adults who are elderly or have underlying 
immunosuppressive and/or cardiopulmonary conditions (Falsey et al., 2005). 
HRSV exists as a single serotype, but has two antigenic subgroups, A and B (Anderson et al., 
1985; Mufson et al., 1985). The attachment G protein, a type II transmembrane glycoprotein 
with little homology to any other known viral protein is the major source of antigenic 
differences between the two HRSV subgroups. Between these subgroups A and B, the G 
protein varies by ~50% in amino acid sequence (Johnson et al., 1987). The nature of these 
differences indicates that the two subgroups represent two lines of divergent evolution, 
rather than variants that differ only at a few major antigenic sites. 
Although the ciliated cells of the respiratory epithelium are the primary site of HRSV 
replication in vivo (reviewed in (Collins et al., 2007)), this virus can infect both human and 
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murine immune system cells, mainly professional antigen-presenting cells (APCs). HRSV 
infection induces maturation in human and murine monocytes and macrophages (Becker et 
al., 1991a; Franke-Ullmann et al., 1995; Midulla et al., 1989; Panuska et al., 1990) and human 
plasmacytoid but not myeloid dendritic cells (Hornung et al., 2004). Upregulation of typical 
activation markers such as CD86 and MHC class II upon HRSV infection of mouse spleen B 
cells was also previously reported (Rico et al., 2009; Rico et al., 2010).  
2. Innate and humoral immunity 
The HRSV infection, as any other pathogenic illness, is controlled by the concerted activity 
of different layers from host immune system. Cells of innate immune response as 
neutrophils infiltrate deeply the airways of ventilated HRSV-infected infants as shown their 
high presence in broncho-alveolar lavage samples of these young patients (Everard et al., 
1994). Also, abundant alveolar macrophages were found in the lower respiratory tract in 
HRSV infection (Becker et al., 1991b). In addition, the depletion of macrophages enhances 
virus titers in the HRSV-infected lung by significant inhibition of early inflammatory 
cytokines release (Pribul et al., 2008). 
Although the humoral response plays no role in the course of a primary infection, the 
protection from subsequent HRSV infections is mediated through antibodies (Abs). In 
mice model, the depletion of B lymphocytes does not alter the clearance of virus in the 
primary infection but the rate of viral clearance after secondary infection was significantly 
decreased (Graham et al., 1991a). Decreased protection from secondary infection 
correlated with low titers of HRSV-specific Abs in the serum of exposed individuals (Mills 
et al., 1971). Also, newborn infants with high titers of maternal acquired Abs are less 
likely to severe bronchiolitis (Holberg et al., 1991). In high-risk infants the passive 
immunization with HRSV-specific Abs reduces hospitalization from HRSV infection (The 
IMpact-RSV Study Group, 1998). 
Vaccination studies using individual HRSV proteins have shown presence of serum Abs 
induced by F, G, M2 and P proteins, but the protection was associated only to the two major 
surface glycoproteins (F and G proteins) (Connors et al., 1991). Two different structures of 
the HRSV F protein: an immature folded form, and other mature cleaved form found in 
virions have been described (Lawless-Delmedico et al., 2000; López et al., 1998). Although 
some neutralizing epitopes of the mature form are not found in the immature F protein, 
both forms induce Ab responses of comparable magnitude (Sakurai et al., 1999). Among 
different virus isolates, the G protein is the less conserved protein: only a 50% identity for G 
protein but a 90% for the F protein between the two antigenic subgroups of HRSV (Collins 
et al., 2007). Therefore, the majority of F-specific but few G-specific monoclonal Abs are 
cross-reactive (Collins et al., 2007) and thus, very few individual G-protein-specific 
monoclonal Abs efficiently neutralize HRSV infectivity. 
Both immunoglobulin A and G play an important role in protection from HRSV infection. 
IgA is largely associated with mucosal immunity. As HRSV initially replicates in apical 
respiratory epithelial cells from the lung airways thus, IgA must be an important factor in 
protection from initial infection. Fast and specific IgA Ab secretion in the upper airways of 
primary HRSV-infected mice could be detected (Singleton et al., 2003). Increased infection in 
human adults correlated with decreased HRSV-specific IgA titers in nasal wash (Walsh & 
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Falsey, 2004). Also, the intranasal administration of HRSV-specific IgA prior to HRSV 
infection enhances the antiviral protection compared with untreated mice (Weltzin et al., 
1994),  although it is not as efficient as administration of HRSV-specific IgG to decrease 
overall pulmonary viral titers in animals (Fisher et al., 1999). In addition, decreased 
incidence of severe disease associated with lower-airway infection was found in both elderly 
and young individuals with high HRSV-neutralizing IgG Ab titers (Falsey & Walsh, 1998; 
Walsh & Falsey, 2004).  
3. Cellular immunity 
Both experimental models and studies in infected infants indicate the key role of cellular 
immunity in the control of infection and the virus-induced complex inflammatory processes 
and airway damage by HRSV. This includes both release of cytokines and chemokines and 
CD4+ or CD8+ responses. 
3.1 Cytokines and chemokines 
In the primary HRSV infection, the airway epithelial cells and lung-resident leukocytes 
secrete cytokines and chemokines quickly. These cell-signaling molecules recruit 
circulating leukocytes to the infected lung that release new cytokines mediating 
proinflammatory functions. Some of these chemokines and cytokines activate and recruit 
immune cells. In contrast, others cytokines and chemokines suppress or regulate the 
proinflammatory state associated to HRSV infection. In summary, this complex cocktail of 
cytokines, chemokines, and different immune system cells are all implicated in HRSV 
disease in humans. Even, differences in immunologic responses at birth may be 
determinant factor of the risk of RSV disease. Comparing cytokines secretion from cord 
blood samples after stimulation with lipopolysaccharide both healthy control children 
and hospitalized infants with HRSV, low IL-1┚, IL-2, IL-4, IL-5, and IL-10 but high IL-6 
and IL-8 responses were found in HRSV-infected young subjects (Juntti et al., 2009). In 
other studies, also reduced phytohemagglutinin-induced IL-13 response (Gern et al., 2006) 
and increased IL-4 secretion (Macaubas et al., 2003) were detected in umbilical cord blood 
cells of infants with risk of severe HRSV infection and asthma. High production of several 
Th2 cytokines such as IL-4, IL-5, and IL-13 has been associated with severe HRSV airway-
disease in infants (Gern et al., 2006). Increased IL-4 was also observed in nasopharyngeal 
secretions of HRSV-infected children compared to control children (Murai et al., 2007). 
These results indicate that a Th2 polarization can enhance HRSV-associated illness. In 
addition, in other study an increased concentration of IL-17 associated to Th17 cells was 
detected in moderately ill patients as compared with severe HRSV cases but the 
mechanism was not elucidated (Larranaga et al., 2009). In this line recently, a role of 
HRSV NS1 protein in the suppression of Th17 response with subsequent decreased 
protective adaptive immunity had been proposed (Munir et al., 2011). 
IFNs are proteins secreted by host cells in response to the presence of viruses among other 
intracellular pathogens. Different viruses generate IFN-suppressive proteins. HRSV 
nonstructural proteins NS1 and NS2 cooperatively interfere with the host antiviral cytokine 
response antagonizing the ┙/ IFN-induced response in infected epithelial cells as well as 
suppressing plasmacytoid dendritic cell maturation (Schlender et al., 2000).  
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3.2 T-cell mediated response 
Although the immune mechanism involved in HRSV disease and protection is not well 
understood, humoral and cellular responses appear to play different roles in the antiviral 
protection, and resolution of HRSV infection as well as disease pathogenesis. The HRSV-
specific antibodies are sufficient to prevent or limit the severity of infection but are not 
required for clearing primary infection (Graham et al., 1991a). However, T cell-mediated 
responses are necessary to abolish viral replication once HRSV infection is established, and 
for the clearance of virus-infected cells in primary infection (Anderson & Heilman, 1995).  
Studies in mice have shown that F and G envelope proteins prime different subsets of CD4+ 
T cells. In this system, G protein primes only CD4+ T cells towards a Th2-type cytokine 
response (Johnson et al., 1998) while F protein primes both CD4+ and CD8+ T cells toward a 
Th1-type biased cytokine response (Alwan & Openshaw, 1993). In contrast, G protein 
primes a mixed Th1/Th2 CD4+ T cell response in humans (De Graaff et al., 2004). 
Using a murine HRSV-infected model in which the CD4+ and CD8+ T-lymphocyte 
subpopulations were depleted individually or together by injections of specific Abs, the role 
of both effector T cells was evaluated. This study showed that both CD4+ and CD8+ 
lymphocyte subsets are important in clearing a primary infection (Graham et al., 1991b). In 
addition, CD4+ T cell responses play key roles in pulmonary pathology during infection. 
IFN-┛ secreting CD4+ T cells (Th1-type cytokine response) clear HRSV in low lung 
pathology, while viral clearance by IL-4 secreting CD4+ cells (Th2-type cytokine response) is 
strongly associated with significant pulmonary damages, including eosinophilic infiltration 
(Alwan et al., 1992; Tang & Graham, 1997). 
HRSV-specific cytolytic T lymphocytes have been detected in peripheral blood 
mononuclear cells from infants with bronchiolitis (Chiba et al., 1989; Isaacs et al., 1987). 
CD8+ T cells with an activated effector cell phenotype could be isolated from 
bronchoalveolar lavage samples and blood of infants with a severe primary respiratory 
HRSV infection (Heidema et al., 2007). Although also, the HRSV infection suppresses lung 
CD8+ T-lymphocyte effector activity by blocking IFN- secretion by the HRSV-specific T 
cells (Chang & Braciale, 2002). In this study, alteration the development of pulmonary 
CD8+ T-cell memory by interfering with TCR-mediated signaling was described (Chang 
& Braciale, 2002). Outstandingly, this fault in effector function was only identified in CD8+ 
T cells from infected lung. In contrast, the effector CD8+ T cells that had migrated from the 
draining lymph nodes to other secondary lymphoid organs had no insufficiency in their 
function. Moreover, the viral load after primary HRSV infection was significantly 
increased in the lungs of IFN-┛ knockout mice compared with wild type mice (Lee et al., 
2008). Thus, during primary HRSV infection the IFN-┛ production is decisive to the 
development of protection against HRSV-associated disease. The poor induction of IFN-┛ 
release by HRSV may contribute possibly to its weak immunogenicity and the frequent 
reinfection observed in the human host. In addition, the analysis of responses in congenic 
mice with different major histocompatibility complex (MHC) haplotypes indicated that 
susceptibility to sequelae after neonatal HRSV infection was predominantly inherited 
(Tregoning et al., 2010). Thus, MHC haplotype and its effect on CD8+ T cell immune 
response play a central role in neonatal HRSV infection. In summary, all these results 
indicate clearly a key role of CD8+ immune response in virus clearance. 
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Human cytotoxic T cells from normal not sick adults recognize almost six proteins: F, N, M, 
M2-1, NS2, and SH but little or no recognition of G, NS1 or P proteins of HRSV was found 
(Cherrie et al., 1992). As only the recognition of F and M2 proteins were associated with a 
recent infection, these data indicate the existence of a long term CD8+ response against 
HRSV (Cherrie et al., 1992). In addition, F, N, and M2 proteins of this virus also induce 
cytolytic T responses in the mouse model (Kulkarni et al., 1993b),(Olson et al., 2008; 
Openshaw et al., 1990; Pemberton et al., 1987).  
4. MHC class I epitopes 
In cellular immunity, the recognition and killing of infected cells by CD8+ cytolytic T 
lymphocytes (CTLs) first requires proteolytic degradation of newly synthesized viral 
proteins in the cytosol by the combined action of proteasomes and degradative peptidases 
(Shastri et al., 2002). This antigen processing generates short peptides of 8 to 12 residues that 
are translocated to the endoplasmic reticulum lumen by transporter associated with antigen 
processing (TAP), and subsequent N-terminal trimming by the metallo-aminoproteases 
ERAP1 and 2 is frequently required (Rock et al., 2004; Saveanu et al., 2005). Peptide binding 
to newly synthesized ┚2-microglobulin and MHC class I heavy chain generates stable 
peptide/MHC complexes. Usually, this interaction is made possible by two major anchor 
residues at position 2 and the C-terminus of the antigenic peptide (Parker et al., 1994; 
Rammensee et al., 1999) that are deeply accommodated into specific pockets of the antigen 
recognition site of the MHC class I molecule (Bjorkman et al., 1987a; Bjorkman et al., 1987b). 
Finally, the stable trimolecular peptide-MHC-┚2-microglobulin complexes are transported to 
the cell membrane and presented for CTL recognition (York et al., 1999).  
Several HRSV epitopes restricted by different MHC class I molecules of the mouse (H-2) or 
human (HLA) have been identified using CTL from seropositive individuals or murine 
models respectively. 
4.1 H-2 class I epitopes 
A study from the early 1990s shown that the cytotoxic activity of lung CD8+ lymphocytes 
correlated with a protective cellular immune response in BALB/c mice vaccinated with a 
recombinant virus expressing the M2 protein of HRSV (Kulkarni et al., 1993a). This protein 
was the only HRSV protein that induced resistance to virus infection in H-2d mice (BALB/c) 
but not in H-2b or H-2k mice (Kulkarni et al., 1993a). The conserved peptide between 
subgroup A and B HRSV strains SYIGSINNI, which spans residues 82-90 of the HRSV M2 
protein, was identified as the immunodominant Kd-restricted CTL epitope in H-2d mice, and 
other two M2 peptides were also identified (the different H-2 class I epitopes of HRSV 
identified are summarized in Table 1)(Kulkarni et al., 1993b). Afterward, a new H-2Kd-
restricted subdominant epitope with the amino acid sequence VYNTVISYI, spanning 
residues 127-135 of the same M2 protein, was also identified (Lee et al., 2007). In addition, 
the frequency of specific T cells responding to two H-2Kd-presented epitopes in the same 
protein following HRSV infection for both lymphoid and nonlymphoid tissues was 
evaluated. In the cellular response to HRSV infection the ratios of specific T lymphocytes for 
M282-90 (dominant) and M2127-135 (subdominant) epitopes were either 3:1 in the spleen or 10:1 
in the lung both in primary response, secondary infection, and memory (Lee et al., 2007). 
www.intechopen.com
 
Human Respiratory Syncytial Virus Infection 
 
8 
Strain H-2 Sequence a Protein Position Reference 
      
BALB/c Kd SYIGSINNI Matrix 2 82-90 
(Kulkarni et 
al., 1993b) 
BALB/c Kd EYALGVVGV Matrix 2 71-79 
(Kulkarni et 
al., 1993b) 
BALB/c Kd NYFEWPPHA Matrix 2 26-34 
(Kulkarni et 
al., 1993b) 
BALB/c Kd VYNTVISYI Matrix 2 127-135 
(Lee et al., 
2007) 
BALB/c Kd KYKNAVTEL Fusion 85-93 
(Chang  
et al., 2001) 
BALB/c Kd ELQLLMQSTPPTNNR Fusion 92-106 
(Jiang  
et al., 2002) 
BALB/c Kd TYMLTNSEL Fusion 249-257 
(Johnstone 
et al., 2004) 
BALB/c Kd TYMLTNSELL Fusion 249-258 
(Johnstone 
et al., 2004) 
C57Bl/6 Db NAITNAKII Matrix 187-195 
(Rutigliano 
et al., 2005) 
      
a The H-2Kd or Db anchor motifs are underlined. 
Table 1. Summary of H-2 class I epitopes of HRSV 
To identify the epitope(s) responsible to the protective CTL response against HRSV F 
protein detected in BALB/c mice (Pemberton et al., 1987) a panel of overlapping synthetic 
peptides corresponding to the complete HRSV F protein sequence of A2 strain was used 
(Chang et al., 2001). The peptide spanning residues 85-93 of this protein was identified as 
the immunodominant H-2Kd-restricted epitope recognized by F-specific CD8+ T cells from 
BALB/c mice. No HRSV F-specific CTL response was associated to H-2Dd or H-2Ld class I 
molecules (Chang et al., 2001).This F-specific CD8+ T cell response was 10-fold lower than 
the dominant M2-specific response during primary HRSV infection. With the same strategy 
of screening a panel of overlapping synthetic peptides a second H-2Kd-restricted epitope for 
HRSV F-specific CD8+ CTL was described (Jiang et al., 2002). This is a long 15-mer peptide 
from the F protein (92–106 residues), which in contrast to other murine HRSV epitopes not 
contain the known allele-specific motif for H-2Kd binding: Tyr at position 2 (P2) and 
aliphatic C-terminal residues (Table 1 and SYFPEITHI database: http://www.syfpeithi.de 
(Rammensee et al., 1999)). All 15 amino acids of this unusual epitope appear to be required 
for effective presentation to CTL. The interaction of 15-mer epitope with the presenting H-
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2Kd class I molecule was not studied. Thus, future studies are needed to clarify this 
intriguing protein structure. 
The use of predictive methods for H-2d binding by means of web software tools enabled the 
identification of a new epitope in the F glycoprotein of the Long strain, F249–258, which is 
presented by Kd as a 9-mer (TYMLTNSEL) or a 10-mer (TYMLTNSELL) peptide (Johnstone 
et al., 2004). No hierarchy in CD8+ T-lymphocyte responses to F85–93 and F249–258 epitopes 
was found in vivo during a primary response. In contrast, F85–93 was found dominant with 
respect to F249–258 in in vivo memory and secondary responses (Johnstone et al., 2004). 
The majority of studies on the HRSV pathogenesis in mice have been performed in the 
BALB/c mice because are among the most permissive mice but several strains of mice are 
also susceptible to HRSV infection (Prince et al., 1979). Overlapping synthetic peptide 
strategy, spanning the F, G, and M proteins of HRSV were used to identify HRSV epitopes 
in H-2b mice (Rutigliano et al., 2005). An H-2Db-restricted CTL epitope from the RSV M 
protein, corresponding to aa 187–195 (NAITNAKII) was identified (Rutigliano et al., 2005). 
In C57Bl/6 mice, M187–195-specific CTLs were activated with similar kinetics to the 
immunodominant epitope M2 82–90 in BALB/c mice. 
4.2 HLA class I epitopes 
The peptide 308NPKASLLSL316 was the first human HRSV-specific CTL epitope identified 
from healthy adult volunteers using a panel of overlapping peptides spanning the HRSV 
nucleoprotein (Goulder et al., 2000). Later with a similar experimental strategy, other four 
viral nucleoprotein epitopes were found associated to HLA-A2 (Terrosi et al., 2007) or –B8 
(Venter et al., 2003) positive donors (Table 2).  
Overlapping peptide approach with the HRSV fusion protein shown the existence of two 
HLA-B57 and –Cw12-restricted CTL epitopes from infants who had just recovered from 
severe HRSV infection (Brandenburg et al., 2000). In the same way, HLA-A1-restricted CTL 
specific for the peptide RELPRFMNYT, spanning residues 109-118 of fusion protein, was 
detected in peripheral blood mononuclear cells from three healthy volunteers (Rock & 
Crowe, 2003). 
Finally, five epitopes derived from the matrix, NS2 and matrix 2 proteins of HRSV were 
identified by selection of peptides with appropriate binding motifs, for four different HLA 
class I alleles (HLA-A1, -A3, -B44 and -B51) using the SYFPEITHI prediction software 
(Rammensee et al., 1999) from healthy donors (Table 2). All epitopes were detected in 4-5 
different individuals suggesting that the dominant epitope was specifically presented by the 
respective HLA class I allele (Heidema et al., 2004).  
Thirteen different HRSV CTL epitopes have been identified either healthy adult donors or 
sick infants (Table 2). They were presented by three HLA-A, five –B, and one –C class I 
molecules indicating broad cellular immune control against this virus. All CD8+ epitopes 
were peptides with the canonical anchor motifs for the respective presenting molecule. 
The exception was the absence of HLA-A1 anchor motif (Asp or Glu at position 3 and 
aromatic C-terminal residue) in the ligand 109RELPRFMNYT118 of the fusion protein (Rock 
& Crowe, 2003), indicating the complexity and plasticity of interactions in HLA-peptide 
complexes.  
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In summary, different CTL epitopes have been identified in five of six HRSV proteins 
previously described as recognized by human CD8+ T lymphocytes by Cherrie et al. 
(Cherrie et al., 1992). Only the identification of CTL epitopes from SH protein remains open 
and future studies are needed.  
 
HLA Sequence a Protein Position Reference 
     
A2 QLLSSSKYT Nucleoprotein 16-24 
(Terrosi  
et al., 2007) 
A2 KMLKEMGEV Nucleoprotein 137-145 
(Terrosi  
et al., 2007) 
B8 VMLRWGVLA Nucleoprotein 258-266 
(Venter 
 et al., 2003) 
A2 ILNNPKASL Nucleoprotein 303-311 
(Terrosi  
et al., 2007) 
B7 NPKASLLSL Nucleoprotein 308-316 
(Goulder  
et al., 2000) 
A1 RELPRFMNYT Fusion 109-118 
(Rock & 
Crowe, 2003) 
B57 RARRELPRF Fusion 118-126 
(Brandenburg 
et al., 2000) 
Cw12 b IAVGLLLYC Fusion 551-559 
(Brandenburg 
et al., 2000) 
B51 IPYSGLLLV Matrix 195-203 
(Heidema  
et al., 2004) 
A1 YLEKESIYY Matrix 229-237 
(Heidema  
et al., 2004) 
B44 AELDRTEEY Matrix 2 64-72 
(Heidema 
 et al., 2004) 
A3 RLPADVLKK Matrix 2 151-159 
(Heidema  
et al., 2004) 
B51 LAKAVIHTI NS2 41-49 
(Heidema  
et al., 2004) 
a The HLA anchor motifs are underlined. 
b No data of HLA-Cw12 anchor motif. 
 
Table 2. Summary of HLA class I epitopes of HRSV 
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5. HLA class I ligands 
In most cases, the natural MHC class I ligand is assumed to be the one that has the canonical 
anchor sites, the minimal length, and the optimal antigenicity when tested as a synthetic 
peptide although some studies indicates that the extrapolation of either antigenicity or MHC 
binding strength is not sufficient to identify natural viral MHC class I ligands (Samino et al., 
2004; Samino et al., 2006). All previous studies identifying several HRSV epitopes in mice 
and human were performed with synthetic peptides and no formal identification of natural 
epitopes was performed. Thus, the high-performance liquid chromatography (HPLC) 
coupled to high sensitivity mass spectrometry could be a useful technology to identify the 
endogenously processed HLA ligands derived from HRSV in infected cells.  
The basic strategy of this experimental approach beginning with the isolation of HLA-
bound peptide repertoires from cells either infected or not infected with HRSV. Next, both 
peptide pools are fractionated by HPLC in consecutive runs and under identical conditions 
to reduce alterations in the peptide elution patterns. Later, every HPLC fraction from each 
peptide pool is analyzed by MALDI-TOF mass spectrometry. Each spectrum of a single 
HPLC fraction of HRSV-infected cells is compared with the equivalent fraction of the 
uninfected cells. This technique allows the selection of peptides found only in the HRSV-
infected cells. Next, the corresponding MS/MS spectrum of each differential peptide is 
obtained by ion-trap mass spectrometry and its amino acid sequence is assigned with 
bioinformatics tools. These sequences could be validated by comparison with the MS/MS 
spectrum of the corresponding synthetic peptide. With this experimental approach, the viral 
amino acid sequence AITNAKII, spanning residues 188-195 of the HRSV matrix protein was 
identified as endogenously processed and presented in infected human cells (Infantes et al., 
2011). This natural ligand is a non canonical HLA-Cw4 ligand that uses alternative 
interactions to the anchor motifs previously described for its presenting HLA-Cw4 class I 
molecule (Table 3).  
Interestingly, the M187-195 NAITNAKII nonamer has been described as an H-2Db-restricted 
CTL epitope (Rutigliano et al., 2005) in the mouse model (Table 1). It has the canonical 
anchor motifs for Db molecules:  Asn at position 5 and aliphatic C-terminal residue (Falk et 
al., 1991). Therefore, two viral peptide species of different lengths that share the same 
antigenic core and differ only in the additional N-terminal residue were bound to either 
HLA-Cw4 or H-2Db presenting molecules in the respective infected cells. Surprisingly, both 
the human octamer and the mouse nonamer bound efficiently to HLA-Cw4 molecules, in 
spite of the lack of canonical anchors for interaction with the presenting molecule.  
In other study that involved culturing virus-infected cells with stable isotope-labeled  amino 
acids expected to be anchor residues for the HLA allele of interest and then performing 
immunoprecipitation of HLA molecules and two-dimensional HPLC-mass spectrometry 
analysis, one HRSV ligand for each HLA-A2 or –B7 class I molecule was identified (Meiring 
et al., 2006) (Table 3). The ligand KLIHLTNAL (residues 33-41 of the NS1 protein) was 
presented by HLA-A2 whereas the peptide KARSTPVTL of the fusion protein was 
endogenously bound to HLA-B7 in human infected cells (Table 3).  
Therefore, in the previous studies only one HRSV ligand restricted by a single HLA 
molecule was presented on the cell membrane surface. Thus, this is the rule? Or conversely, 
could a particular HLA molecule bind several ligands of this small virus simultaneously? To 
www.intechopen.com
 
Human Respiratory Syncytial Virus Infection 
 
12
answer this question, HLA-B27 ligands isolated from large amounts of human healthy or 
HRSV-infected cells were compared using mass spectrometry technologies. This analysis 
demonstrated the existence of nine naturally processed HLA-B27 ligands from six different 
HRSV proteins in the same infected cells (Infantes et al., 2010) (Table 3). Thus, the nine 
detected ligands represent 2% of the proteome of this small virus, which is monitored by the 
same HLA class I allele. If these data are typical for all HLA class I molecules, the cellular 
immune response would monitor ~ 12% of the proteome of this viral pathogens in 
heterozygous HLA-A, -B and -C infected individuals. These data suggest that the cellular 
immune pressure could be high in some small viruses as HRSV. 
HLA Sequence a Protein Position Reference 
     
Cw4 AITNAKII Matrix 188-195 
(Infantes  
et al., 2011) 
A2 KLIHLTNAL NS1 33-41 
(Meiring  
et al., 2006) 
B7 KARSTPVTL Fusion 551-559 
(Meiring  
et al., 2006) 
B27 HRQDINGKEM Nucleoprotein 100-109 
(Infantes  
et al., 2010) 
B27 RRANNVLKNEM Nucleoprotein 184-194 
(Infantes  
et al., 2010) 
B27 KRYKGLLPKDI Nucleoprotein 195-205 
(Infantes  
et al., 2010) 
B27 SRSALLAQM Matrix 76-84 
(Infantes  
et al., 2010) 
B27 VRNKDLNTL Matrix 169-177 
(Infantes  
et al., 2010) 
B27 KRLPADVLKK Matrix 2 150-159 
(Infantes  
et al., 2010) 
B27 GRNEVFSNK Polymerase 2089-2097 
(Infantes  
et al., 2010) 
B27 LRNEESEKMAK Phosphoprotein 198-208 
(Infantes  
et al., 2010) 
B27 HRFIYLINH NS2 37-45 
(Infantes  
et al., 2010) 
a The HLA anchor motifs are underlined. 
Table 3. Summary of natural HLA class I ligands of HRSV identified by mass spectrometry. 
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6. Perspectives of HLA-ligand-based vaccine development against HRSV 
HRSV lacks effective approved vaccine or antiviral therapy. Worldwide, this virus remains 
one of the pathogens deemed most important for vaccine development (Hall, 1994). Over 
the last decades, several efforts have been made towards HRSV vaccine development using 
different experimental approaches (reviewed in (Murata, 2009)), including inactivated or 
live attenuated virus strains, vector-based, and viral protein subunit/DNA-based 
candidates. Also, against pathogens under cellular immune control as HRSV, the 
polyepitope vaccine approach could be valuable. This vaccine comprises a recombinant 
DNA construct inserted into a viral genome (generally vaccinia or adenovirus) encoding a 
chimerical protein where distinct HLA class I-restricted epitopes from one or more 
pathogens are expressed. Currently, polyepitope vaccine to coinduce multiple CTL 
responses directed towards a number of different protein target antigens are being used 
against diseases produced by different pathogens including arenavirus, Epstein Barr virus, 
HIV, malaria and even several cancers (reviewed in (Suhrbier, 2002)) but not with HRSV. 
These multiepitope vaccines are thermostable, safe, easy to manufacture, and cost effective. 
In this context, the identification of pathogen-derived peptides bound to HLA molecules by 
high resolution mass spectrometry is an emerging focus of HLA-ligand-based vaccine 
development (Ovsyannikova et al., 2007). In addition, as mutations that enable escape from 
host cellular immunity against HRSV do not appear to accumulate with time (Collins et al., 
2007), thus this virus could be a candidate particularly adequate to the multiepitope vaccine 
therapeutic approach. 
7. Conclusion  
HRSV is the single most important cause of serious lower respiratory tract illnesses such as 
bronchiolitis and pneumonia in infants and young children. Mild infections of this virus 
occur in healthy adults but HRSV poses a serious health risk in immunocompromised 
individuals and in the elderly. Although the immune mechanisms involved in HRSV 
disease and protection are not fully understood the CD8+ T lymphocytes are required to 
clear virus-infected cells. In last decades, several HRSV epitopes restricted by different MHC 
class I molecules of the mouse (H-2) or human (HLA) have been identified using murine 
models or CTL of seropositive individuals respectively. In recent years, using mass 
spectrometry analysis of complex HLA-bound peptide pools, physiologically processed 
HLA ligands from HRSV have been identified. This knowledge could be used in the 
peptide-based vaccine development. 
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